Illumina, Inc.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

Illumina reported Q3 FY26 revenue of $1.13 billion, up 4.2% year-over-year (7.6% growth excluding tariff refunds), with results above guidance driven by healthy clinical demand and robust NovaSeq X placements. GAAP diluted EPS was $1.43 versus $0.98 a year earlier; non-GAAP diluted EPS excluding tariff refunds was $1.44. Free cash flow rose to $378 million from $253 million. Management raised FY26 guidance: revenue to $4.64-$4.66 billion (from $4.60-$4.64 billion) and non-GAAP diluted EPS to $5.40-$5.45 (from $5.30-$5.40). The company remains on China's Unreliable Entities List, and Greater China is excluded from ROW organic growth metrics.

•3d ago

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

Illumina introduced three early-access capabilities on its BioInsight Platform: Workflow Orchestrator, DRAGEN Ultra, and Learning Cohorts, aimed at automating end-to-end genomic informatics at scale. DRAGEN Ultra extends analysis beyond variant calling using AI models; its new dnaAI variant-prioritization model produced an 8% increase in disease associations across unsolved cases and ranked known disease-associated variants in the top four candidates in 99.4% of genomes analyzed. The BioInsight Platform debuted last week, and the announcement was made at the ASHG annual meeting in Montreal — a routine early-access software expansion rather than a commercial or financial milestone.

•11d ago

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Illumina launched the BioInsight Platform, its first unified software environment combining analysis applications, genomics-focused AI, and curated biological data for genomic and multiomic research. The launch includes DRAGEN v4.6 with new deployment options across cloud and standard CPU environments, plus access to the SpliceAI2 model for rare disease research. The platform moves Illumina's informatics portfolio to a usage-based BioInsight Credits model replacing annual subscriptions, and will be showcased at the ASHG annual meeting in Montreal.

•18d ago

Illumina releases SpliceAI2 to help advance rare disease research

Illumina introduced SpliceAI2, a next-generation genomic AI model for predicting splice variants, targeting rare disease research, hereditary cancer testing research, and drug discovery. In benchmarks on Genomics England cohort data, SpliceAI2 identified 17% more disease-relevant splice variants than competing models and improved splice site usage quantification by 34% versus the next best model. The model was trained on a dataset 100 times larger than the original SpliceAI, which has been cited in over 3,400 publications. SpliceAI2 joins PromoterAI and PrimateAI-3D in Illumina's suite of genomic AI models, which collectively enable researchers to identify up to twice as many variants with predicted biological impact. The tool is available through Illumina's BioInsight applications including DRAGEN Annotation and Emedgene, supporting the company's push into software and AI-driven revenue streams.

•24d ago

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

AGNC Investment will be added to the S&P MidCap 400 effective prior to the open of trading on Monday, September 21, 2026, as part of S&P Dow Jones Indices' quarterly rebalance. The same reshuffle sends Bloom Energy, Illumina, and Everpure to the S&P 500, while The Trade Desk, Molson Coors Beverage, and Builders FirstSource drop from the S&P 500 to the S&P SmallCap 600. Funds benchmarked to the MidCap 400 will need to buy AGNC shares at the effective date, which can produce a short-lived mechanical bid rather than a fundamental re-rating.

•1mo ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Illumina reported Q2 revenue of $1.16 billion, up 9.5% year-over-year, with ROW organic revenue growth reaching 8.1% driven by demand for NovaSeq X. Management raised full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP EPS guidance to $5.30-$5.40, citing momentum in clinical sequencing applications. Free cash flow for the quarter was $162 million, while the balance sheet remains robust with $1.17 billion in cash and short-term investments.

•3mo ago

Illumina expands Billion Cell Atlas program with new AI drug developers

Illumina expanded its Billion Cell Atlas alliance by adding three new members, including AI-native drug developer Formation Bio, to leverage genome-wide perturbation data for drug discovery. The program, originally launched in January 2026 with founding members AstraZeneca, Merck, and Eli Lilly, has now sequenced over 350 million cells and generated six petabytes of genomic data across more than 200 disease-relevant cell lines. Partners will utilize this dataset to build virtual cell models, validate targets, and improve clinical trial designs, aiming to de-risk the development of new therapeutics.

•3mo ago

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

Illumina launched StrataMap Spatial, a sequencing-based spatial transcriptomics solution that offers whole-transcriptome profiling at single-cell resolution. The platform detects twice as many genes per sample as probe-based competitors and integrates with existing NovaSeq and NextSeq instruments, lowering the barrier to entry for current customers. Early pilot data from Beth Israel Deaconess Medical Center and Cancer Research UK demonstrates the tool's ability to map complex tissues, including lymphatic vessels and glioma microenvironments.

•4mo ago

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

Illumina and Integrated DNA Technologies (IDT) announced a strategic collaboration to integrate IDT’s library prep workflows with Illumina’s DRAGEN secondary analysis software. The new 'DRAGEN Somatic for IDT Custom Panels' pipeline is optimized for IDT’s xGen FFPE and cfDNA custom panels, featuring a new low-quality FFPE mode to improve analysis of degraded samples. This integration connects IDT’s wet-lab solutions to Illumina’s software ecosystem, aiming to reduce downstream analysis burden and accelerate insights for somatic oncology research.

•5mo ago

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Illumina and SPT Labtech launched fireflyGO, a benchtop automation platform for library preparation that integrates with the MiSeq i100 sequencer. The solution automates workflows for Pillar Biosciences oncoReveal targeted oncology panels, aiming to reduce hands-on time and improve reproducibility in cancer research. Illumina also expanded its oncoReveal portfolio with the Nexus 21 Gene Panel for solid tumors and hematological malignancies, and an 84-gene Lymphoid Panel for B-cell and T-cell conditions.

•5mo ago

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

Illumina launched its first distributed whole-genome sequencing solution for molecular residual disease (MRD) research, targeting solid tumors and blood cancers. The workflow, built on the NovaSeq X platform, offers 10 ppm sensitivity and 99.5% specificity, with a turnaround time of five days. It is currently in early access for select partners, including Mayo Clinic, with a global commercial launch planned for next year. This release positions Illumina to capture a larger share of the growing MRD market by enabling labs to perform WGS-based MRD detection in-house, rather than relying solely on centralized providers.

•5mo ago